Literature DB >> 7710927

Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.

R Kramer1, T K Weber, R Arceci, N Ramchurren, W V Kastrinakis, G Steele, I C Summerhayes.   

Abstract

Characterisation of altered glycosylation of P-glycoprotein (P-gp) found associated with the absence of a multidrug resistance (MDR) phenotype in cell lines prompted an investigation to assess the role of post-translational processing in establishing P-gp efflux pump functionally. The clone A cell line used in this study displays a strong MDR phenotype mediated by high constitutive levels of expression of P-gp. Incubation of clone A cells with tunicamycin for different periods resulted in a time-dependent increase in daunorubicin accumulation, reflecting a reduction in P-gp function. Parallel experiments conducted with verapamil resulted in no loss of P-gp functionality in clone A cells. Reduction in surface-associated P-gp following exposure to tunicamycin was established by FACS analysis, Western blot analysis and immunoprecipitation of surface-iodinated P-gp. In addition, immunoprecipitation of P-gp from 32P-orthophosphate-labelled cells demonstrated reduced phosphorylation of P-gp associated with tunicamycin exposure. From these studies we conclude that glycosylation of P-gp is required to establish the cellular MDR phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710927      PMCID: PMC2033717          DOI: 10.1038/bjc.1995.133

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells.

Authors:  N D Richert; L Aldwin; D Nitecki; M M Gottesman; I Pastan
Journal:  Biochemistry       Date:  1988-10-04       Impact factor: 3.162

2.  Phosphorylation of the multidrug resistance associated glycoprotein.

Authors:  W Mellado; S B Horwitz
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

3.  Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters.

Authors:  H Hamada; K Hagiwara; T Nakajima; T Tsuruo
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

4.  Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

5.  Effects of tunicamycin on anthracycline resistance in P388 murine leukemia cells.

Authors:  T H Chou; D Kessel
Journal:  Biochem Pharmacol       Date:  1981-11-15       Impact factor: 5.858

6.  Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.

Authors:  W T Beck; M C Cirtain
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

7.  Functional expression of human mdr1 in the yeast Saccharomyces cerevisiae.

Authors:  K Kuchler; J Thorner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells.

Authors:  L M Greenberger; S S Williams; E Georges; V Ling; S B Horwitz
Journal:  J Natl Cancer Inst       Date:  1988-06-01       Impact factor: 13.506

9.  Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells.

Authors:  T C Chambers; E M McAvoy; J W Jacobs; G Eilon
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

10.  Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein.

Authors:  J Staats; D Marquardt; M S Center
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

View more
  11 in total

1.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

2.  Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator.

Authors:  Xiu-Bao Chang; April Mengos; Yue-Xian Hou; Liying Cui; Timothy J Jensen; Andrei Aleksandrov; John R Riordan; Martina Gentzsch
Journal:  J Cell Sci       Date:  2008-08-05       Impact factor: 5.285

3.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

4.  Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells.

Authors:  Donavon C Hiss; Gary A Gabriels; Peter I Folb
Journal:  Cancer Cell Int       Date:  2007-04-18       Impact factor: 5.722

5.  Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Authors:  Tamás Micsik; András Lőrincz; Tamás Mersich; Zsolt Baranyai; István Besznyák; Kristóf Dede; Attila Zaránd; Ferenc Jakab; László Krecsák Szöllösi; György Kéri; Richard Schwab; István Peták
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

6.  MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.

Authors:  Tamás Micsik; András Lőrincz; János Gál; Richard Schwab; István Peták
Journal:  Diagn Pathol       Date:  2015-12-30       Impact factor: 2.644

7.  Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.

Authors:  Yanlong Ji; Shasha Wei; Junjie Hou; Chengqian Zhang; Peng Xue; Jifeng Wang; Xiulan Chen; Xiaojing Guo; Fuquan Yang
Journal:  Oncotarget       Date:  2017-02-21

8.  N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma.

Authors:  Takeaki Kudo; Hiroaki Nakagawa; Masato Takahashi; Jun Hamaguchi; Naoya Kamiyama; Hideki Yokoo; Kazuaki Nakanishi; Takahito Nakagawa; Toshiya Kamiyama; Kisaburo Deguchi; Shin-Ichiro Nishimura; Satoru Todo
Journal:  Mol Cancer       Date:  2007-05-09       Impact factor: 27.401

Review 9.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Leonardo Freire-de-Lima; José Osvaldo Previato; Lucia Mendonça-Previato; Márcia Alves Marques Capella
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

10.  L1210 Cells Overexpressing ABCB1 Drug Transporters Are Resistant to Inhibitors of the N- and O-glycosylation of Proteins.

Authors:  Lucia Pavlikova; Mario Seres; Milan Hano; Viera Bohacova; Ivana Sevcikova; Tomas Kyca; Albert Breier; Zdena Sulova
Journal:  Molecules       Date:  2017-07-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.